Project Grant R01CA285674
- This federal Project Grant award of $161,000.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports a pilot study by the University of Connecticut (UConn) to explore communication about sexuality and intimacy among individuals with metastatic breast cancer (MBC) and their partners. The key objectives of the study are to: 1) identify themes in MBC patients' communication about sexuality and intimacy, 2) determine if specific...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $178,453.00 to Duke University to conduct a pilot randomized controlled trial to improve engagement with vaginal dilator therapy among female cancer survivors who underwent pelvic radiation therapy. The study aims to develop, refine, and test a novel behavioral intervention to address modifiable biopsychosocial barriers to dilator therapy engagement, such as symptom burden,...
- The University of Texas MD Anderson Cancer Center received a $825,966 Project Grant from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to conduct a randomized controlled trial of a multilevel, culturally adapted storytelling intervention. The project aims to address stigma at both the patient and provider levels to improve cancer outcomes for Zambian women living with cancer and HIV. The patient-level intervention will randomly assign 240 participants to...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $3,277,279 to Tufts Medical Center to develop and evaluate English and Spanish smartphone-based Embodied Conversational Agents (ECAs) that promote follow-up care for patients with abnormal cervical cancer screening results. The 4-year project aims to address gaps in follow-up rates, which can be as high as 20% for those diagnosed with cervical cancer. The ECAs will provide...
- The U.S. National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) has awarded a $1,270,070 Project Grant to the Medical College of Wisconsin, Inc. to conduct the Self-Sampling to Optimize Anal Lesion Outcomes (SOLO) study. The objective of this 5-year study is to use a randomized controlled trial to test the effect of self-sampling on attendance at cytology and high-resolution anoscopy (HRA) appointments among sexual and gender minority populations, including those with HIV...
- The Project Grant award of $637,596.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to develop and test a video-based intervention to reduce defensive cancer information avoidance and increase the reach of colorectal cancer screening messaging. The intervention is designed to increase self-efficacy and positive affect among those who typically avoid colorectal cancer information, with the goal of improving screening rates. The project includes a...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will provide $402,401 to the University of Missouri System to conduct a pilot study on the feasibility and impact of a metacognitive strategy training (MCST) intervention for women with cancer-related cognitive impairment (CRCI) following breast cancer treatment. The study aims to examine the effects of MCST on cognitive performance, frontoparietal neural functioning, and functional...
- This $1,716,332 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund a randomized clinical trial of a targeted palliative care intervention called TARGET-PC for patients with metastatic breast cancer. The study aims to improve documentation of end-of-life care preferences, delivery of end-of-life care, and participant-reported outcomes. Using a validated prediction model, the researchers will identify and enroll 400 high-risk...
- This Project Grant award from the National Institute on Minority Health and Health Disparities (CFDA 93.307 - Minority Health and Health Disparities Research) totaling $165,012 provides funding for a feasibility and acceptability study of a multi-level, community-engaged intervention to increase access to cervical cancer screening using HPV self-collection outreach among high-risk women in a rural North Carolina county. The key objectives are to: 1) Develop a Community Advisory Board to inform...
- This Project Grant award from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) provides $442,750 to New York University to conduct a Delphi study on implementation strategies for cervical cancer control policies in Africa. The study aims to: (A) identify determinants of successful policy implementation in low- and middle-income countries (LMICs) using the Consolidated Framework for Implementation Research (CFIR), (B) qualitatively understand the...
PROMOTING EFFECTIVE CLINICAL COMMUNICATION ABOUT SEXUAL HEALTH AFTER GYNECOLOGIC CANCER: A RANDOMIZED CONTROLLED TRIAL OF A PATIENT-FOCUSED INTERVENTION - PROJECT SUMMARY SEXUAL PROBLEMS ARE COMMON, DISTRESSING AND PERSISTENT FOR PATIENTS WITH GYNECOLOGIC CANCER (GC). YET MOST PATIENTS WITH GC WHO EXPERIENCE SEXUAL CONCERNS DO NOT RAISE THEM WITH THEIR CLINICIANS, OFTEN DUE TO A LACK OF PREPARATION FOR HOW TO DO SO EFFECTIVELY. NEGATIVE BELIEFS, SUCH AS LOW SELF-EFFICACY FOR INITIATING DISCUSSIONS OF SEXUAL HEALTH OR EXPECTATIONS FOR THE DISCUSSION, FURTHER LIMIT PATIENTS' ACTIVE ENGAGEMENT IN THESE DISCUSSIONS. A PATIENT-FOCUSED THEORY-GUIDED INTERVENTION, STARTING THE CONVERSATION (STC), COULD BE IDEALLY SUITED TO ADDRESS THESE CHALLENGES AND EMPOWER PATIENTS TO DRIVE CLINICAL DISCUSSIONS TO MEET THEIR NEEDS. STC WAS DEVELOPED FOR USE WITH BREAST CANCER (BC) PATIENTS AND FOUND EFFECTIVE IN THAT POPULATION. COMPARED TO BC PATIENTS, HOWEVER, GC PATIENTS UNDERGO DIFFERENT TREATMENTS, EXPERIENCE UNIQUE SEXUAL HEALTH CONCERNS, AND HAVE DISTINCT NEEDS FOR A SEXUAL HEALTH COMMUNICATION INTERVENTION. THEREFORE, WE MODIFIED STC TO SUIT THE NEEDS OF WOMEN WITH GC AND CONDUCTED A PILOT TRIAL OF THE NEW INTERVENTION, CALLED STC - GYNECOLOGIC CANCER (STC-GC), FINDING STRONG SUPPORT FOR ITS FEASIBILITY AND ACCEPTABILITY. BEFORE THIS INTERVENTION CAN BE DISSEMINATED, ITS EFFICACY IN THE TARGET POPULATION MUST BE EVALUATED. THE PRIMARY OBJECTIVE OF THE PROPOSED STUDY IS THUS TO EVALUATE THE EFFICACY OF THE STC-GC INTERVENTION AMONG PATIENTS TREATED FOR GC REPORTING SEXUAL CONCERNS. FEMALE PATIENTS WITH ANY STAGE GC (N=200) WILL BE RANDOMIZED TO RECEIVE EITHER THE STC-GC INTERVENTION [VIDEO, WORKBOOK, AND RESOURCE GUIDE] OR TO A CONTROL [USUAL CARE PLUS RESOURCE GUIDE]. IN AIM 1, WE WILL EVALUATE THE EFFICACY OF STC-GC IN FACILITATING PATIENT CLINICAL COMMUNICATION ABOUT SEXUAL HEALTH (PRIMARY), ASSESSED USING RIGOROUS DIALOGUE ANALYSIS OF PATIENTS' CLINICAL COMMUNICATION ABOUT SEXUAL HEALTH, AND IN IMPROVING PATIENTS' SEXUAL AND PSYCHOLOGICAL HEALTH OUTCOMES AT POST-INTERVENTION AND 2- AND 6-MONTH FOLLOW-UP (SECONDARY). IN AIM 2, WE WILL EXAMINE WHETHER INTERVENTION-RELATED INCREASES IN PATIENTS' SELF-EFFICACY AND OUTCOME EXPECTANCIES FOR SEXUAL HEALTH COMMUNICATION MEDIATE EFFECTS OF STC-GC ON PATIENTS' COMMUNICATION (AIM 2A) AND WHETHER ENHANCED SEXUAL HEALTH COMMUNICATION MEDIATES EFFECTS OF STC-GC ON PATIENTS' SEXUAL AND PSYCHOLOGICAL HEALTH OUTCOMES (AIM 2B). IN AIM 3, WE WILL CONDUCT IN-DEPTH QUALITATIVE INTERVIEWS WITH A PURPOSIVE SAMPLE OF PATIENTS IN STC-GC AND WITH CLINICIANS OF GC PATIENTS TO PROVIDE INFORMATION FROM MULTIPLE PERSPECTIVES TO CONTEXTUALIZE AND INTERPRET THE QUANTITATIVE FINDINGS OF THE TRIAL. AS THE FIRST EFFICACY TRIAL OF A SEXUAL HEALTH COMMUNICATION INTERVENTION FOR WOMEN WITH GC, FINDINGS FROM THIS STUDY WILL BE INSTRUMENTAL IN ADVANCING EFFORTS TO INTEGRATE SEXUAL HEALTH INTO ROUTINE CANCER CARE. FURTHER, THE PROPOSED STUDY HAS A NUMBER OF UNIQUE FEATURES, INCLUDING A QUALITATIVE INVESTIGATION OF MULTIPLE PERSPECTIVES, NOVEL APPLICATION OF DIALOGUE ANALYSIS, ANALYSIS OF MULTIPLE INTERVENTION MEDIATORS, AND A MEDICALLY INCLUSIVE PATIENT POPULATION, WHICH HEIGHTEN STUDY IMPACT AND INNOVATION. DATA FROM THIS STUDY WILL SERVE AS THE PLATFORM FOR A FUTURE DISSEMINATION TRIAL OF STC-GC IN MULTIPLE SETTINGS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $488.6k | 7/22/25 | ||
| Not listed | $475.3k | 7/1/24 |